Artikel dengan mandat akses publik - Zhe-Sheng ChenPelajari lebih lanjut
Tidak tersedia di mana pun: 50
Modulating ROS to overcome multidrug resistance in cancer
Q Cui, JQ Wang, YG Assaraf, L Ren, P Gupta, L Wei, CR Ashby Jr, ...
Drug Resistance Updates 41, 1-25, 2018
Mandat: US National Institutes of Health
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)
H Zhang, H Xu, CR Ashby Jr, YG Assaraf, ZS Chen, HM Liu
Medicinal research reviews 41 (1), 525-555, 2021
Mandat: US National Institutes of Health
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
J Dong, Z Qin, WD Zhang, G Cheng, AG Yehuda, CR Ashby Jr, ZS Chen, ...
Drug Resistance Updates 49, 100681, 2020
Mandat: National Natural Science Foundation of China
The combination of disulfiram and copper for cancer treatment
H Li, J Wang, C Wu, L Wang, ZS Chen, W Cui
Drug discovery today 25 (6), 1099-1108, 2020
Mandat: National Natural Science Foundation of China
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
B Li, J Jiang, YG Assaraf, H Xiao, ZS Chen, C Huang
Drug Resistance Updates 53, 100720, 2020
Mandat: National Natural Science Foundation of China
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters
YF Fan, W Zhang, L Zeng, ZN Lei, CY Cai, P Gupta, DH Yang, Q Cui, ...
Cancer letters 421, 186-198, 2018
Mandat: US National Institutes of Health, National Natural Science Foundation of China
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
K Pang, ZD Shi, LY Wei, Y Dong, YY Ma, W Wang, GY Wang, MY Cao, ...
Drug Resistance Updates 66, 100907, 2023
Mandat: National Natural Science Foundation of China
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
L Gao, ZX Wu, YG Assaraf, ZS Chen, L Wang
Drug Resistance Updates 57, 100770, 2021
Mandat: National Natural Science Foundation of China
A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway
S Xu, H Yao, S Luo, YK Zhang, DH Yang, D Li, G Wang, M Hu, Y Qiu, ...
Journal of Medicinal Chemistry 60 (4), 1449-1468, 2017
Mandat: National Natural Science Foundation of China
miR200c attenuates P-gp–mediated MDR and metastasis by targeting JNK2/c-jun signaling pathway in colorectal cancer
H Sui, GX Cai, SF Pan, WL Deng, YW Wang, ZS Chen, SJ Cai, HR Zhu, ...
Molecular cancer therapeutics 13 (12), 3137-3151, 2014
Mandat: National Natural Science Foundation of China
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
M Huang, Y Lin, C Wang, L Deng, M Chen, YG Assaraf, ZS Chen, W Ye, ...
Drug resistance updates 64, 100849, 2022
Mandat: National Natural Science Foundation of China
Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance
Y Zhou, E Hopper-Borge, T Shen, XC Huang, Z Shi, YH Kuang, ...
Biochemical pharmacology 77 (6), 993-1001, 2009
Mandat: US National Institutes of Health
Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu (II)
BB Hasinoff, X Wu, AA Yadav, D Patel, H Zhang, DS Wang, ZS Chen, ...
Biochemical Pharmacology 93 (3), 266-276, 2015
Mandat: US National Institutes of Health, Canadian Institutes of Health Research
Exploration of 1, 2, 3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance
B Wang, B Zhao, ZS Chen, LP Pang, YD Zhao, Q Guo, XH Zhang, Y Liu, ...
European Journal of Medicinal Chemistry 143, 1535-1542, 2018
Mandat: National Natural Science Foundation of China
Development of alectinib-based PROTACs as novel potent degraders of anaplastic lymphoma kinase (ALK)
S Xie, Y Sun, Y Liu, X Li, X Li, W Zhong, F Zhan, J Zhu, H Yao, DH Yang, ...
Journal of medicinal chemistry 64 (13), 9120-9140, 2021
Mandat: National Natural Science Foundation of China
Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors
S Yuan, B Wang, QQ Dai, XN Zhang, JY Zhang, JH Zuo, H Liu, ZS Chen, ...
Journal of Medicinal Chemistry 64 (19), 14895-14911, 2021
Mandat: National Natural Science Foundation of China
Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia
L Long, YG Assaraf, ZN Lei, H Peng, L Yang, ZS Chen, S Ren
Drug Resistance Updates 52, 100703, 2020
Mandat: National Natural Science Foundation of China
Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-a]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators
S Wang, SQ Wang, QX Teng, L Yang, ZN Lei, XH Yuan, JF Huo, XB Chen, ...
Journal of Medicinal Chemistry 63 (24), 15979-15996, 2020
Mandat: National Natural Science Foundation of China
Discovery of potent inhibitors against P-glycoprotein-mediated multidrug resistance aided by late-stage functionalization of a 2-(4-(pyridin-2-yl) phenoxy) pyridine analogue
Y Ma, D Yin, J Ye, X Wei, Y Pei, X Li, G Si, XY Chen, ZS Chen, Y Dong, ...
Journal of Medicinal Chemistry 63 (10), 5458-5476, 2020
Mandat: National Natural Science Foundation of China
Identification of a potent oridonin analogue for treatment of triple-negative breast cancer
H Yao, S Xie, X Ma, J Liu, H Wu, A Lin, H Yao, D Li, S Xu, DH Yang, ...
Journal of Medicinal Chemistry 63 (15), 8157-8178, 2020
Mandat: National Natural Science Foundation of China
Informasi terbitan dan pendanaan ditentukan secara otomatis oleh program komputer